Pages that link to "Q44713017"
Jump to navigation
Jump to search
The following pages link to Interactions of olopatadine and selected antihistamines with model and natural membranes (Q44713017):
Displaying 15 items.
- Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis (Q34166101) (← links)
- Membrane permeability alteration of some bacterial clinical isolates by selected antihistaminics (Q34986348) (← links)
- Ocular allergy treatment comparisons: azelastine and olopatadine (Q35790957) (← links)
- A review of olopatadine for the treatment of ocular allergy (Q35871885) (← links)
- Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model (Q36072416) (← links)
- A review of the use of olopatadine in allergic conjunctivitis (Q36104875) (← links)
- Roles of histamine and its receptors in allergic and inflammatory bowel diseases (Q36132180) (← links)
- Modeling kinetics of subcellular disposition of chemicals. (Q37194304) (← links)
- Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies (Q37257725) (← links)
- Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. (Q37716013) (← links)
- The expanding role of H1 antihistamines: a patent survey of selective and dual activity compounds 2005-2010. (Q37780551) (← links)
- Rhamnolipids elicit the same cytotoxic sensitivity between cancer cell and normal cell by reducing surface tension of culture medium. (Q38955572) (← links)
- Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops (Q39956528) (← links)
- In vitro antibacterial activity of some antihistaminics belonging to different groups against multi-drug resistant clinical isolates (Q42863101) (← links)
- Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge (Q46846459) (← links)